Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$63.47 ▼ -0.49
(-0.77%)
MKT CAP: $5.63B • VOL: 782.7K
52W L $36 52W H $81
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$53
MEDIAN
$71
MEAN
$72
HIGH
$86
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CGON TAPE
CGON // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $76.80 | $72.99 | 2025-02-14 | $57.76 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $79.97 | $74.89 | 2025-02-06 | $59.66 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $72.36 | $69.82 | 2025-01-29 | $60.93 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $64.74 | — | 2025-01-17 | $62.20 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $55.85 | $60.30 | 2025-01-09 | $56.49 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $75.53 | $66.01 | 2024-12-18 | $55.22 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $61.57 | $64.10 | 2024-12-04 | $59.03 | -4.3% | 48% | C |